AV2 Antiviral Spray Versus Placebo in Human Papillomavirus Cervix Infections
Status:
Unknown status
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
This study aims to prove that, by a one-time topical spray on the cervix, AV2-DM is an
effective antiviral in reducing on short term (3 months) the human papillomavirus (HPV)
infection.
- Primary endpoint: significant drop in viral load AV2-DM versus placebo
- Secondary endpoint:the number of patients with adverse events